Sleep apnea ages your blood vessels faster — and researchers now know why
Sleep apnea doesn’t just leave you tired. New research shows it accelerates vascular aging through a specific biological mechanism — one that researchers may already know how to target.
Sleep apnea affects hundreds of millions of people worldwide, most of them undiagnosed. During sleep, the airway repeatedly collapses, causing brief but frequent interruptions to breathing and oxygen supply. The condition has long been linked to elevated cardiovascular risk — higher rates of hypertension, heart attack, and stroke. But the precise biological pathway connecting those nightly oxygen dips to damaged arteries has remained murky. New mouse research points to a culprit: cellular senescence.
Cells that stop working but refuse to die
Senescent cells are damaged or stressed cells that have stopped dividing but evade the normal process of programmed cell death. Instead, they accumulate in tissues and continuously release a cocktail of inflammatory proteins — a state researchers call the senescence-associated secretory phenotype, or SASP. That chronic low-grade inflammation degrades surrounding tissue. In blood vessels, it manifests as stiffening, calcification, and an accelerated trajectory toward atherosclerosis.
In the new study, researchers exposed mice to intermittent hypoxia — repeated short periods of low oxygen — mimicking the pattern of oxygen deprivation that occurs during sleep apnea episodes. The mice developed a significantly higher burden of senescent cells in their vascular walls, alongside measurable deterioration in cardiovascular function. When the researchers treated the mice with senolytics — drugs specifically designed to clear senescent cells — vascular function improved. The causal chain, from hypoxia to senescence to vascular dysfunction to recovery through senolytic intervention, held up across multiple measures.
What this means beyond the mouse model
The finding fits into a broader research movement that views cellular senescence as a central driver of multiple age-related diseases simultaneously, rather than a side effect of individual conditions. Senolytic drugs are already in clinical trials for conditions ranging from pulmonary fibrosis to diabetic kidney disease. Whether they can reverse vascular aging in humans with sleep apnea is not yet known.
The current standard treatment for sleep apnea — CPAP therapy, which keeps the airway open during sleep — reduces symptoms and lowers cardiovascular risk, but does not reverse existing vascular damage. If senescent cell burden accumulates during years of untreated or undertreated apnea, CPAP alone may not be enough to undo the biological aging that has already occurred. The question now is whether senolytics could serve as an adjunct therapy — not just managing the condition, but actively repairing the vascular harm it has caused. Human trials to test that hypothesis don’t yet exist.